NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...

A pore smaller than one nanometer reads peptide sequences amino acid by amino acid, pinpointing single-site Alzheimer's ...

A refined base-pair editor limits unintended neighboring DNA edits while maintaining strong correction of disease-causing ...

The European Commission (EC) has approved an extension of Johnson & Johnson’s Rybrevant (amivantamab) marketing authorization ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...

Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...

Every blue-eyed person you have ever met carries the same genetic fingerprint, a single mutation buried deep inside a gene ...

She walked into the room as an ordinary volunteer — and walked out believing she had superhuman strength. After a series of psychological cues and carefully staged reactions, she became convinced her ...

RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related ...

This valuable study presents a theoretical model of how punctuated mutations influence multistep adaptation, supported by empirical evidence from some TCGA cancer cohorts. This solid model points to ...